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In Brief
Hock et al. show that hypertonic stress
leads to cytoplasmic translocation and
loss of function of neuronal FUS in a
stress granule-independent manner.
Stress-induced FUS translocation results
from impaired Transportin-mediated
nuclear import. Astrocytes are resistant
to cytoplasmic FUS mislocalization upon
hypertonic pressure and lack
pathological protein accumulations in
FTD-FUS brains.
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https://doi.org/10.1016/j.celrep.2018.06.094SUMMARY
The primarily nuclear RNA-binding protein FUS
(fused in sarcoma) forms pathological cytoplasmic
inclusions in a subset of early-onset amyotrophic
lateral sclerosis (ALS) and frontotemporal dementia
(FTD) patients. In response to cellular stress, FUS is
recruited to cytoplasmic stress granules, which are
hypothesized to act as precursors of pathological in-
clusions. We monitored the stress-induced nucleo-
cytoplasmic shuttling of endogenous FUS in an
ex vivo mouse CNS model and human neural net-
works. We found that hyperosmolar, but not oxida-
tive, stress induced robust cytoplasmic translocation
of neuronal FUS,with transient nuclear clearance and
lossof function. Surprisingly, this reaction is indepen-
dent of stress granule formation and the molecular
pathways activated by hyperosmolarity. Instead, it
represents a mechanism mediated by cytoplasmic
redistribution of Transportin 1/2 and is potentiated
by transcriptional inhibition. Importantly, astrocytes,
which remain unaffected inALS/FTD-FUS, are spared
from this stress reaction that may signify the initial
event in the development of FUS pathology.
INTRODUCTION
The RNA/DNA-binding protein FUS (fused in sarcoma) has been
implicated in the pathogenesis of two devastating neurodegen-
erative diseases, amyotrophic lateral sclerosis (ALS) (Kwiatkow-
ski et al., 2009; Vance et al., 2009) and frontotemporal dementiaC
This is an open access article und(FTD) (Neumann et al., 2009). ALS is characterized by progres-
sive paralysis due to motor neuron degeneration, whereas FTD
patients suffer from cognitive impairment, caused by atrophy
of the frontal and temporal brain lobes. Despite distinct symp-
toms, both diseases are clinically, pathologically, and genetically
linked, and have possible common underlying causes, involving
aberrant localization and aggregation of RNA-binding proteins
(Ling et al., 2013).
FUS is a ubiquitously expressed ribonucleoprotein (RNP) with
several RNA-binding domains that allow its involvement in
various steps of RNA metabolism (Lagier-Tourenne et al.,
2010). FUS regulates splicing events important for neuronal
maintenance (Lagier-Tourenne et al., 2012), by associating
with multiple spliceosomal complexes (Rappsilber et al., 2002;
Zhou et al., 2002), such as the minor spliceosome (Reber et al.,
2016) and nuclear splicing speckles (Meissner et al., 2003).
An atypical nuclear localization signal (PY-NLS) retains FUS
predominantly in the nucleus via its interaction with the nuclear
import receptors Transportin 1 and 2 (collectively called TNPO)
(Dormann et al., 2010; Zhang and Chook, 2012). However,
FUS is a shuttling protein that performs additional cytoplasmic
functions, including regulation of axonal mRNA transport and
local translation (Ederle and Dormann, 2017). The N-terminal re-
gion of FUS comprises a low complexity region (LCR) involved in
protein-protein interactions, which renders the protein highly ag-
gregation prone (Sun et al., 2011) and is predicted to attain prion-
like properties (Cushman et al., 2010). In disease, FUS forms
cytoplasmic inclusions in neurons and some types of glial cells,
leading to reduction of available functional protein. Apart from
loss of essential RNA processing functions, pathological misloc-
alization and aggregationmay be toxic because of distorted RNA
and protein interactions and mRNP (messenger RNP) dynamics
(Bowden and Dormann, 2016).ell Reports 24, 987–1000, July 24, 2018 ª 2018 The Author(s). 987
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Under stress conditions, cells form cytoplasmic stress gran-
ules (SGs), dynamic membrane-less organelles, which contain
diverse tightly associated RNA-binding proteins (RBPs) with
LCRs, including FUS (Anderson and Kedersha, 2009; Bentmann
et al., 2012; Bosco et al., 2010; Dormann et al., 2010). SGs were
hypothesized to act as precursors of aggregates, an idea
strongly corroborated by the presence of other SG proteins in
pathological FUS inclusions (Dormann et al., 2010) and by
in vitro data showing that liquid-like FUS droplets mature over
time from a dynamic to an aggregated state (Burke et al.,
2015; Murakami et al., 2015; Patel et al., 2015). Nevertheless,
no experimental demonstration of such a physiopathological
transition within cells exists to date. Moreover, in the cellular
context, nuclear compartmentalization of FUS would have to
be overcome before conversion into cytoplasmic deposits oc-
curs. In fact, SG recruitment was mostly demonstrated for FUS
variants rendered artificially cytoplasmic, mimicking FUS-ALS
cases. In these cases, mutations in the C-terminal PY-NLS
disrupt binding to the nuclear import receptor TNPO1 (Dormann
et al., 2010; Kwiatkowski et al., 2009; Vance et al., 2009), causing
the initial cytoplasmic shift. In FTD-FUS cases, however, no FUS
mutations have been found. Nonetheless, abnormal loss of argi-
nine methylation of FUS, as well as coaggregation of FET pro-
teins (EWS, TAF15) (Neumann et al., 2011) and their common
import factor TNPO1 (Brelstaff et al., 2011), indicate a potential
defect in nuclear shuttling.
Hyperosmolarity causes cell shrinkage due to osmosis-driven
water efflux, and thus has many direct effects, such as elevated
intracellular ionic strength and macromolecular crowding (Burg
et al., 2007). SG formation due to hyperosmolar stress has
been described to recruit exceptionally high levels of nuclear
wild-type FUS in cell lines (Sama et al., 2013). However, it is un-
known whether this response is recapitulated in the CNS and
could thus provide a mechanism for FUS mislocalization to the
cytoplasm independently of NLS mutations.
In this study, we sought to decipher the response of endog-
enous wild-type FUS to hyperosmotic stress in two systems
mimicking the mouse and human brain environment. We
found robust mislocalization of endogenous neuronal FUS
with partial nuclear clearance due to hyperosmotic pressure,
but not oxidative or other types of cellular stress. Surprisingly,
FUS reactivity was independent of SG formation and occurred
in a cell-type-specific manner, because astrocytic FUS was
unaffected in these conditions. Furthermore, FUS exited the
nucleus via passive diffusion rather than active export, and
its redistribution was not driven by activation of the typical
cellular osmotic stress-response pathways. Transcriptional in-
hibition potentiated the observed response, which involved
cytoplasmic redistribution and reduced shuttling of TNPO dur-
ing hyperosmotic stress. Other TNPO cargo proteins showed
a similar response to FUS, whereas proteins shuttling inde-
pendently of TNPO and other import receptors were unaf-
fected. We propose that this phenomenon denotes a cellular
mechanism for reducing nuclear activity of RBPs, through
their rapid redistribution to the cytoplasm. Our findings have
important implications for neurodegeneration, the predisposi-
tion of neurons to form FUS cytoplasmic inclusions, and the
apparent lack of astrocytic pathology in FUS proteinopathies,988 Cell Reports 24, 987–1000, July 24, 2018including ALS-FUS (Mackenzie et al., 2011) and FTLD-FUS
(this study).
RESULTS
Osmotic, but Not Oxidative, Stress Drives Cytoplasmic
Translocation of Endogenous Neuronal FUS
To understand the involvement of cellular stress in the initiation
of FUS pathology, we used mouse brain organotypic cortico-
hippocampal slices, which are morphologically similar to the
intact CNS (Figure S1A). We first tested the effect of hyperos-
molar stress on SG formation and recruitment of FUS. Indeed,
in cortical neurons, T-cell intracellular antigen-1 receptor
(TIAR)-positive SGs were formed in the cytoplasm, most prom-
inently at 4 hr of osmotic stress (Figure 1A). Moreover, nuclear
FUS started to move into the cytoplasm at 2 hr, whereas at 4 hr
of osmotic stress large amounts of FUS were redistributed,
leading to partial nuclear clearance (Figures 1A and 1B). Cyto-
plasmic FUS was then colocalized with TIAR in a granular
pattern indicating its association with SGs (Figures 1A and
1B). Interestingly, if osmotic pressure was applied continu-
ously, cells adapted, SGs disassembled, and FUS relocalized
to the nucleus, as early as 8 hr after stress initiation. Once
adapted, cells survived with no observable signs of stress or
FUS reaction for up to 7 days in hyperosmotic medium (Fig-
ure 1A). Quantification of cytoplasmic FUS in cortical neurons
revealed a significant increase of up to 42% at 4 hr post-stress,
compared with 12% in non-treated conditions, and reversal to
pre-treatment levels by 8 hr (Figure 1C). This effect could also
be validated in hippocampal neurons (Figure S1B). Despite this
strong mislocalization, overall FUS protein levels were unaf-
fected (Figure S1C) and its solubility to different detergents re-
mained unchanged (Figure S1D).
To determine whether human neuronal FUS also reacts to hy-
perosmolar stress, we explored our recently established human
neural stem cells (NSCs), which can be differentiated into mature
neural cultures (data not shown). Indeed, in human neurons, nu-
clear FUSmoved to the cytoplasm and neuronal processes, and
colocalized with the SGmarker protein G3BP (Ras GTPase-acti-
vating protein-binding protein) in a granular pattern (Figure 1D). A
significant increase in cytoplasmic FUS, albeit without the nu-
clear clearance seen in mouse neurons, was detected already
within 15min of osmotic stress and intensified over a time course
of 4–8 hr (Figure 1E). In contrast with mouse neurons in slice cul-
tures, no complete recovery was seen in the human neuronal
network upon continuous osmotic pressure. However, from
8 hr onward, several recovering neurons with relocalized nuclear
FUSwere observed, indicating the same principal mechanism of
adaptation and recovery. However, some cells lost their morpho-
logical integrity, apparently unable to cope with cellular stress
(Figure S1E). This varying adaptability was also reflected in the
large variability observed in cytoplasmic FUS quantification at
96 hr (Figure 1E).
It was previously shown that FUS is recruited to SGs induced
by oxidative stress (Andersson et al., 2008). However, in mouse
brain slices, cytoplasmic SGs elicited by oxidative stress (OX)
did not recruit FUS (Figure 1B). In only a minor subset of cells,
very intense TIAR granules contained small amounts of FUS
Figure 1. Osmotic, but Not Oxidative, Stress
DrivesCytoplasmic Translocation of Endog-
enous Neuronal FUS
(A) Time course of hyperosmolar stress induced by
0.4 M sorbitol in mouse organotypic cortico-hip-
pocampal brain slices. Nuclear FUS started to
redistribute to the cytoplasm at 2 hr and reached a
peak at 4 hr, when it colocalized with cytoplasmic
SGs marked by TIAR. It dynamically relocalized to
the nucleus within 8 hr, when TIAR granules were
also resolved. FUS then stayed unaffected during a
time course of 7 days of continuous stress.
(B) Osmotic stress elicited a distinct response of
FUS, whereas oxidative stress could not sequester
nuclear FUS into cytoplasmic TIAR-positive SGs
induced by 0.5 mM arsenite.
(C) Quantification of neuronal FUS outside the
nucleus showed the dynamic reaction of normally
nuclear neuronal FUS, moving out to the cyto-
plasm at 4 hr and returning to the nucleus at 8 hr in
mouse brain slices (n = 33–58 images from 6 in-
dependent experiments; data are represented as
box and whisker plot).
(D) Time course of hyperosmolar stress in NSC-
derived human neurons. Upon stress, FUS mis-
clocalized to cytoplasmic granules, costained with
the SG marker G3BP.
(E) Quantification of FUS outside the nucleus in
human neuronal cultures across the hyperosmolar
stress time course. A significant portion of FUS
mislocalized to the cytoplasm already at 15 min of
hyperosmotic stress (3 independent experiments,
n = 10–30; data are represented as box and
whisker plot).
(F) Osmotic stress led to splicing defects in the
minigene SCN4A in NSC-34 cells as seen by the
significantly decreased ratio of spliced to total
target mRNA in qRT-PCR results at 2 hr of osmotic
stress, whereas nine control mRNAs were not
significantly affected (data are represented as
mean with SD).
Merged images always include nuclear DAPI
staining. NT, non-treated; OSM, hyperosmolar
stress.(Figure S1F). Confirming our observations in mouse brain slices,
human neuronal FUS also showed a very distinct reaction to
oxidative stress (Figure S1H), with most protein remaining
nuclear, despite prominent cytoplasmic SGs (Figure S1G) and
minor amounts of FUS rarely detected in large SGs (Figure S1G,
arrow).
We verified that FUS redistribution is a general response to hy-
perosmolar stress using sucrose in brain slices (Figures S1I and
S1J). Interestingly, no induction of SGs or FUS cytoplasmic
translocation was seen using urea (Figure S1K), which is a
neutral solute and can move freely in and out of cells without
inducing hypertonic pressure. Similarly, hypoosmolar stress
induced no visible shift of nuclear FUS (Figure S1L), indicating
that the robust cytoplasmic redistribution of FUS is specific to
hypertonic pressure.Hyperosmolar Stress Leads to Loss of Nuclear FUS
Function
Based on the drastic shift of FUS from its normal nuclear locali-
zation to the cytoplasm, we speculated that its nuclear function
might be compromised under stress. To test this, we measured
the splicing levels of SCN4A (sodium voltage-gated channel
alpha subunit 4), a minor intron-containing transcript that is
directly regulated by FUS (Reber et al., 2016). In motor neuron-
like NSC-34 cells, we observed a strong reduction of spliced-
to-total SCN4A ratios during osmotic stress with no change of
FUS levels (Figures 1F, S1M, and S1N). This observation resem-
bles the effect seen after FUS knockdown or cytoplasmic mis-
localization due to ALS-associated mutations in NLS (Reber
et al., 2016). In contrast, nine control mRNAs, whose splicing is
FUS independent (Reber et al., 2016), displayed no significantCell Reports 24, 987–1000, July 24, 2018 989
Figure 2. Cytoplasmic Translocation of FUS
Is Independent of Stress Granule Formation
(A) FUS redistribution to the cytoplasm with partial
nuclear clearance caused by osmotic stress was
not reversed by SG inhibitors (CHX, Em) in neurons
within mouse brain slices. Upon SG inhibition, both
FUS and TIAR showed a diffused pattern, indi-
cating the successful prevention of SG formation.
(B) Quantification of cytoplasmic FUS in neurons
confirmed significant mislocalization also during
SG inhibition (n = 18–25; data are represented as
box and whisker plot).
(C) No change of FUS behavior upon osmotic
stress was seen in human neurons when SG for-
mation was blocked.
(D) Quantification of human FUS outside of the
nucleus confirms significant redistribution also
during SG inhibition (n = 10; data are represented
as box and whisker plot).
(E) Diffuse cytoplasmic FUS localization upon SG
inhibition was especially obvious in NSC-34 cells in
comparison with distinct SGs labeled by G3BP in
the absence of SG inhibitors.
(F) Although treatment with a DYRK inhibitor (GSK-
626616) for 4 hr at the peak of osmotic stress
stabilized TIAR-positive SGs in mouse slice cul-
tures, FUS escaped these and returned to the
nucleus with unchanged kinetics.
Merged images always include nuclear DAPI
staining. In, inhibitor; NT, non-treated; OSM, hy-
perosmolar stress.splicing alterations upon osmotic stress, indicating a functional
impairment of FUS during osmotic stress.
Cytoplasmic Translocation of FUS Is Independent
of Stress Granule Formation
To understand the molecular mechanism of this cytoplasmic
translocation during osmotic stress, we tested whether SG for-
mation was necessary to sequester FUS to the cytoplasm.
Thus, we treated organotypic slices and human neurons with
cycloheximide (CHX) and emetine (Em), which are translational
inhibitors known to block SG formation (Kedersha et al., 2000).
After excluding that CHX or Em alone altered FUS localization
(Figure S2A), we verified that both reagents inhibit SGs (Fig-
ure S2B) and block protein synthesis (Figure S2C). Surprisingly,
neither treatment reversed the robust cytoplasmic localization of
FUS (Figures 2A–2D), whichwas diffusely distributed to the cyto-
plasm in the absence of SGs (Figures 2A, 2C, and 2E).990 Cell Reports 24, 987–1000, July 24, 2018In linewith theseobservations,SGstabi-
lization with a DYRK inhibitor (dual-speci-
ficity tyrosine-regulated kinase, GSK-
626616), which was previously shown to
prevent SG disassembly (Wippich et al.,
2013), did not prolong cytoplasmic FUS
localization. Even though GSK-626616
treatment stabilized TIAR-positive SGs
for an additional 4 hr, FUS escaped these
structures and relocated to the nucleus
with kinetics similar to cells treated onlywith sorbitol (Figure 2F). Collectively, these data indicate that
cytoplasmic FUS redistribution in hyperosmolar conditions is SG
independent, and that dynamic FUS nucleocytoplasmic shuttling
is unaffected by alterations in SG kinetics.
FUS Redistribution to the Cytoplasm Is Independent
from Hyperosmolar Stress Pathways
Osmotic shock is known to activate the three main mitogen-acti-
vated protein kinase (MAPK) signaling pathways involving p38,
extracellular-signal-regulated kinase (ERK), and c-Jun N-termi-
nal kinase (JNK), and others including Src family kinases Fyn
and Syk, as well as protein kinase C (PKC) (Sheikh-Hamad and
Gustin, 2004). In agreement with this, we confirmed the activa-
tion of MAPK cascades upon hyperosmotic treatment in mouse
brain slices, human neurons, and NSC-34 cells (Figures S3A–
S3C). To test their potential role in FUS subcellular redistribution
during osmotic stress, we used a panel of pharmacological
Figure 3. FUS Redistribution to the Cyto-
plasm Is Independent from Hyperosmolar
Stress Pathways
(A and B) Treatment of NSC-34 cells with inhibitors
of stress-activated kinases and pathways did not
interfere with stress-induced FUS mislocalization,
shown in representative images at 2 hr OSM (A)
and quantification of FUS outside the nucleus
during the stress time course (B) (n = 7–10, data are
represented as box and whisker plot). No signifi-
cant reduction was observed in any of the condi-
tions tested except the early time points of PKC
inhibition (30 min: p = 0.0083, 1 hr: p = 0.0005),
whereas rather increased amounts of cytoplasmic
FUS were observed upon SRC inhibition (1 hr:
p = 0.0285, 2 hr: 0.0229) and DNA PK inhibition at
30 min (p = 0.0103).
(C) Inhibition of the main MAPK by their respective
inhibitors (ERK by UO126, p38 by SB202190,
JNK by SP600125) was confirmed by immunoblots
for phosphorylated forms or ERK and JNK (ph-
ERK and ph-JNK, respectively) or phosphorylation
of a downstream p38 target (ph-ATF2), whereas
their levels did not change. Representative immu-
noblots and average of the densitometry quantifi-
cation of three replicates are plotted with SEM.
(D) Reduction of the master osmoregulator
TonEBP by siRNA did not alter FUS cytoplasmic
redistribution upon stress.
Merged images always include nuclear DAPI
staining. ctrl, control; In, inhibitor; NT, non-treated;
OSM, hyperosmolar stress.inhibitors. Inhibition of ERK1/2, p38, and JNK was confirmed by
decreased phosphorylation either of the kinases themselves or
their respective targets. Nevertheless, this inhibition did not pre-
vent cytoplasmic FUS accumulation during stress (Figures 3A–
3C). Similarly, inhibiting Src-family kinases or PKC did not
reduce sorbitol-induced FUS relocalization at 2 hr of osmotic
stress, whereas a slight decrease in cytoplasmic FUS was
seen upon PKC inhibition at 30 min and 1 hr. Osmotic stress
was also reported to trigger DNA damage (Dmitrieva et al.,
2004; K€ultz and Chakravarty, 2001), which in turn leads to FUS
nuclear exit, a process controlled by its phosphorylation by
DNA-dependent protein kinase (DNA-PK) (Deng et al., 2014).
However, whereas FUS remains nuclear when DNA-PK is in-
hibited upon staurosporine treatment (Figure S3D), no effect
on sorbitol-induced mislocalization was observed by DNA-PK
inhibition (Figures 3A and 3B).
A major mediator of the osmotic stress response is the tran-
scription factor TonEBP (tonicity response element binding pro-
tein), whose activation induces the expression of osmoprotec-
tive target genes. Although we observed activation of TonEBP
by its nuclear translocation in osmotic conditions, no change
was observed on FUS cytoplasmic mislocalization after downre-gulation of TonEBP by small interfering RNA (siRNA) (Figure 3D).
Our results indicate that FUS redistribution is independent of the
major signaling pathways activated by hyperosmolar stress.
FUS Leaves the Nucleus by Passive Diffusion upon
Osmotic Stress
To decipher the underlying mechanism for FUS redistribution
during osmotic stress, we next investigated its nuclear exit route,
including receptor-mediated transport, in complex with mRNA
or passive diffusion. Because a CRM1/Exportin-1-dependent
leucine-rich nuclear export signal has been predicted within
the FUS RNA recognition motif (RRM) domain, we first tested
whether this export factor is active during hyperosmolar stress.
We found that FUS redistribution was not prevented by leptomy-
cin B (LMB) (Figures 4A and 4B), although CRM1 effectively in-
hibited shuttling of its known targets p62 and REV (Kudo et al.,
1999; Pankiv et al., 2010) (Figures S4A and S4B). This indicated
that FUS leaves the nucleus independently of CRM1-mediated
export during sorbitol-induced stress.
Second, we tested whether FUS utilizes the mRNA export ma-
chinery to exit the nucleus by silencing Aly/REF, an essential fac-
tor of the TREX (transcription-export) complex, necessary forCell Reports 24, 987–1000, July 24, 2018 991
Figure 4. FUS Leaves the Nucleus by Pas-
sive Diffusion upon Osmotic Stress
(A and B) Inhibition of CRM1/Exportin1 by lep-
tomycin B (LMB) in NSC-34 cells did not prevent
FUS cytoplasmic localization upon osmotic stress,
shown in representative images (A) and quantifi-
cation of FUS outside the nucleus (B) (n = 7–8 im-
ages, data are represented as box and whisker
plot).
(C) Despite mRNA retention in the nucleus, caused
by siRNA-mediated knockdown of the mRNA
export complex factor Aly/Ref, FUS accumulated
in the cytoplasm upon osmotic stress.
(D–G) Quantification of FUS outside the nucleus (D)
was performed in single cells with retained nuclear
polyAmRNA as confirmed in (E) (n = 11–17 images,
data are represented as box and whisker plot).
(F–G) NSC-34 cells transfected with artificially
enlarged FUS constructs displayed a size-depen-
dent restriction of FUS movement across the nu-
clear membrane in osmotic stress. Addition of
sorbitol led to cytoplasmic mislocalization of
endogenous and FLAG-tagged FUS in their stan-
dard time frame, whereas GFP-FUS and GR2-
GFP2-FUS showed delayed export kinetics,
depending on their respective size as seen in
representative images (F) and quantification of
different FUS constructs outside the nucleus (G)
(n = 9–11 images, data are represented as box and
whisker plot).
Merged images always include nuclear DAPI
staining. nt, non-transfected; NT, non-treated;
OSM, hyperosmolar stress.transporting mRNAs through the nuclear pore complex (NPC)
(Katahira, 2012; Sloan et al., 2016). Accumulation of polyA
mRNA in nuclei upon decreased Aly/REF expression confirmed
inhibition of mRNA export (Figures 4C and 4E), but did not result
in nuclear retention of FUS when osmotic stress was applied in
parallel (Figures 4C and 4D). Hence, hyperosmolarity-induced
FUS mislocalization did not depend on functional mRNA export.
Lastly, we tested whether passive diffusion could be the main
exit mechanism. We hypothesized that increasing the size of
FUS would decrease its movement through the nuclear pores,
because passive diffusion rate is mainly dependent onmolecular
mass (Timney et al., 2016). To test this, we used a combination of
differently sized FUS constructs, apart from endogenous FUS,
including FLAG-tagged FUS (FLAG-FUS; 54.5 kDa), single
EGFP-tagged FUS (GFP-FUS; 90 kDa), and a fusion FUS protein
containing two glucocorticoid receptor (GR) hormone-binding
domains coupled with two EGFPs (GR2-GFP2-FUS; 172 kDa).
Even though FLAG-FUS could exit the nucleus with kinetics992 Cell Reports 24, 987–1000, July 24, 2018similar to the endogenous protein, signifi-
cantly reduced amounts of GFP-FUS
were found in the cytoplasm (Figures 4F
and 4G). Although the initially cytosolic
GR2-GFP2-FUS rapidly translocated into
the nucleus upon dexamethasone addi-
tion (Figure S4C) (Ederle et al., 2018), its
artificial size increase almost completelyprevented its exit during stress, whereas endogenous FUS was
redistributed to the cytoplasm in the same cells (Figure S4D).
Our enlarged version of the CRM1 cargo protein REV (GR-
GFP-REV) confirmed that active receptor-mediated export was
not altered under these conditions (Figure S4C). Collectively,
these data indicate that FUS leaves the nucleus by passive diffu-
sion under osmotic conditions, in line with the mechanism used
under physiological conditions (Ederle et al., 2018).
Osmotic Stress-Induced FUS Redistribution Is
Potentiated by Transcriptional Inhibition
The primarily nuclear FUS localization under physiological condi-
tions (Figure 1A) implies that steady-state nuclear import is higher
than export. The large amounts of cytoplasmic FUSobserved un-
der osmotic stress therefore indicate either increased exit or
decreased nuclear import. Augmented egress out of the nucleus
can be explained by higher diffusion rate across the nuclear
membrane, which is limited by macromolecular size, suggesting
that FUS partitioning in higher-molecular-weight nuclear com-
plexes may favor its nuclear localization (W€uhr et al., 2015).
Indeed, FUS was shown to bind numerous pre-mRNAs (Lagier-
Tourenne et al., 2012) and to interact with RNA polymerase II
(Pol II) (Bertolotti et al., 1996, 1998; Schwartz et al., 2012) and
splicing complexes in the nucleus.
In line with known effects during osmotic stress (Finan and
Guilak, 2010), we observed alterations in DNA and nuclear
speckle organization (Figures S5A and S5B). Such stress-
induced rearrangements may abolish some nuclear interac-
tions of FUS and lead to more free FUS able to diffuse out
of the nucleus. Indeed, some studies have found a slight redis-
tribution of FUS into the cytoplasm (Zinszner et al., 1994) and
loss of nuclear FUS foci upon actinomycin D (ActD) treatment
(Patel et al., 2015). ActD inhibits transcription by interfering
with Pol II progression (Trask and Muller, 1988), leading to a
reduced supply of newly synthesized mRNA transcripts, which
in combination with possible disruption of larger transcription
and splicing complexes might increase FUS diffusion. To
test this, we treated cells with ActD with or without hyperos-
molar stress. Although we could not detect a cytoplasmic shift
in human neurons upon ActD treatment alone, combination of
ActD with osmotic stress led to a strong synergistic effect
with significant increase in cytoplasmic FUS, compared with
solely osmotic stress (Figure 5A). Interestingly, in NSC-34 cells
we detected some cytoplasmic FUS upon transcriptional inhi-
bition alone, either by ActD (Figure S5C) or as an inhibitor
selectively targeting Pol II (DRB) (Figure S5D), as described
before (Kino et al., 2011; Zinszner et al., 1994). This finding in-
dicates that decreased possibilities for RNA binding and com-
plex formation in the nucleus might increase FUS diffusion
through nuclear pores, even in the absence of stress. Yet, hy-
perosmolar pressure strongly amplifies this effect in neurons
and NSC-34 cells.
Cytoplasmic Translocation of FUS upon Hypertonic
Pressure Results from Insufficient Import by TNPO
A shift in FUS subcellular distribution might also be caused by
insufficient nuclear import, which is effectively executed by
TNPO (Dormann et al., 2010; Lee et al., 2006). To test a potential
TNPO import defect, we monitored its cargo proteins hnRNPA1
(heterogeneous nuclear RNP A1), TAF15, and EWS upon hyper-
osmolar stress and confirmed their cytoplasmic shift in mouse
brain slices (Figures 5B and 5C) and human neurons (Figure 5D).
The same effect was detected for all other tested TNPO cargo
proteins, including SAM68 (Figure S5E) and hnRNPA2B1 (Fig-
ure S5F), as well as the neuronal marker NEUN (Figure 1A), which
also contains a PY-NLS (Dredge and Jensen, 2011). To exclude
that sorbitol induces a general leakage of the nuclear membrane,
we verified that the non-shuttling protein heterogeneous nuclear
ribonucleoprotein U (hnRNPU) retained its nuclear localization
upon osmotic stress (Figure S5G). We then wondered whether
other shuttling proteins employing different import receptors
were also affected. The functionally related, ALS-associated
protein TDP-43, which uses a classical NLS recognized by im-
portin a/b (Dormann and Haass, 2011), did not translocate to
the cytoplasm upon osmotic stress in brain slices (Figure 5E)
or human neurons (Figure 5D). Similarly, the importin a/b cargop53 (Liang and Clarke, 1999) accumulated in nuclear patches
upon sorbitol treatment (Figure S5H), as previously described
(Nakaya et al., 2009). These findings indicate that hyperosmolar
stress did not impair all transport through the nuclear pore, but
specifically TNPO-mediated nuclear import.
Due to the specificity of this stress response, we then moni-
tored TNPO expression and localization during hyperosmolar
stress. Although protein levels did not change (Figure S5I), its
subcellular localization was altered (Figure 5F). TNPO was
dispersed throughout the cytoplasm and the nucleoplasm under
physiological conditions, while upon osmotic pressure it dis-
played a significant shift toward the cytoplasm in a manner
that correlated with FUS redistribution in neurons (Figures 5F
and 5G), as well as NSC-34 cells (Figures S5J–S5M). In the cyto-
plasm TNPO1 localized to SGs together with FUS and the SG
marker eIF3h (eukaryotic initiation factor 3); however, inhibiting
SG formation did not prevent the cytoplasmic shift of TNPO1
(Figure S5K). This response was specific for TNPO, because
Importin 7, which is normally dispersed in the nucleus and cyto-
plasm, did not show a change in subcellular localization (Figures
S5L and S5M).
We next asked whether increased TNPO levels could rescue
the sorbitol-induced FUS relocalization. Interestingly, overex-
pressing HA-tagged TNPO1 in NSC-34 cells led to two distinct
cell populations with a differing reaction to osmotic stress.
Although in some cells HA-TNPO1 was detained in the cyto-
plasm upon stress like its endogenous counterpart, in a subpop-
ulation of cells HA-TNPO1 localized largely to the nucleus and
was able to cause a clear recovery of nuclear FUS localization
(Figure 5H).
Taken together, based on the specificity of the cargo misloc-
alization and its rescue by nuclear TNPO, we hypothesize that
TNPO cytosolic retention contributed to redistribution of FUS
and other cargos. Overall, the observed hyperosmolar stress
response mimics a loss of TNPO function, as previously
described (Dormann et al., 2010). Upon osmotic stress, this spe-
cific TNPO and cargo exclusion from the nucleus might repre-
sent a physiological stress response.
Astrocytes Are Spared from Stress-Induced
Cytoplasmic Translocation of FUS
One advantage of organotypic slice cultures is the presence and
interplay of all different cell types found in the CNS. During our
initial osmotic stress experiments we noticed that, although re-
acting cells showed a very strong FUS mislocalization, certain
cells did not respond at all. Using cell-type-specific markers dur-
ing the stress time course, we confirmed a strong and dynamic
FUS redistribution in all neurons (Figure 1A), as well as in micro-
glia (Figures 6A and S6A). Notably, the neuronal marker NEUN,
which is also an RBP involved in splicing (Kim et al., 2009),
formed a similar granular pattern during stress (Figure 1A), sug-
gesting that it is sequestered in SGs. In contrast, astrocytes
identified by GFAP (glial fibrillary acidic protein) remained unal-
tered during 8 hr of continuous stress, while surrounding
GFAP-negative cells reacted strongly (Figures 6B and S6B). To
test whether human astrocytic FUS is similarly non-reactive to
hyperosmolar stress, we used distinct neuronal and astrocytic
cultures derived from our human NSCs. Intriguingly, humanCell Reports 24, 987–1000, July 24, 2018 993
Figure 5. Osmotic Stress-Induced FUS
Redistribution Is Potentiated by Transcrip-
tional Inhibition and Results from Insuffi-
cient Import by TNPO
(A) Quantification of FUS outside the nucleus in
human neurons revealed the synergistic effect of
transcriptional inhibition by ActD and osmotic
pressure compared with either factor alone (n = 10
images; data are represented as box and whisker
plot).
(B) hnRNPA1 displayed a dynamic reaction similar
to FUS during osmotic stress in neurons in mouse
brain slices.
(C) TAF15 strongly localized to the cytoplasm upon
osmotic stress in neurons of mouse brain slices,
whereas EWS mislocalized to a lesser extent.
(D) Quantification of cytoplasmic protein levels in
human neurons confirmed the mislocalization of
hnRNPA1, TAF15, and EWS (n = 10–15 images), but
notTDP-43,uponosmotic stress (n=13–15 images;
data are represented as box and whisker plot).
(E) TDP-43 did not shift to the cytoplasm upon
osmotic stress, whereas TIAR-positive SGs were
formed.
(F) TNPO1 nucleocytoplasmic equilibrium shifted
toward the cytoplasm upon osmotic stress in
human neurons, correlating with cytoplasmic FUS
mislocalization.
(G) Quantification of cytoplasmic TNPO1 in human
neurons confirmed a significant shift upon os-
motic stress (n = 18–20 images; data are repre-
sented as box and whisker plot).
(H) Overexpression of HA-tagged TNPO rescued
FUS mislocalization, when TNPO could shuttle to
the nucleus (a), whereas surrounding non-trans-
fected cells showed the standard osmotic stress-
induced response. In a subpopulation of trans-
fected cells, HA-tagged TNPO1 was retained in the
cytoplasm (b) and did not rescue FUS localization.
Merged images always include nuclear DAPI stain-
ing. NT, non-treated; OSM, hyperosmolar stress.astrocytes were non-reactive to this insult, because FUS re-
mained nuclear in both pure astrocytic cultures (Figure 6C) and
astrocytes found within the neural network (Figure S6C). This
resistance to osmotic stress was maintained over a period of
multiple days and represents a distinct reaction compared with
neuronal FUS (Figure 6D). In line with the observation in neurons,
FUS was not sequestered into the cytosol because of oxidative
stress in astrocytic cultures, despite the formation of bona fide
SGs labeled with G3BP and eIF3h (Figure S6D).
Despite Their Reaction to Hyperosmolarity, Astrocytes
Do Not Show This TNPO-Specific Stress Response
Because neurons and astrocytes were derived from the same
human NSCs, we tested whether these progenitor cells show
sensitivity to osmotic stress and if so, at which time point in dif-
ferentiation cells with astrocytic fate lose their sensitivity. Undif-
ferentiated NSCs showed a strong sensitivity to osmotic stress,
and FUSwas driven to the cytoplasm in cells labeled by the stem
cell marker SOX2 (sex determining region Y, box 2) and low
levels of MAP2/NEFM (microtubule-associated protein 2/neuro-
filament medium polypeptide). Interestingly, only 3 days into dif-994 Cell Reports 24, 987–1000, July 24, 2018ferentiation, a subpopulation of cells with slightly larger nuclei
exhibited decreased reactivity to osmotic stress. These cells
had lost SOX2 and the neuronal markers MAP2/NEFM, and
showed an altered VIM (vimentin) pattern, which is highly ex-
pressed in astrocytes, indicating that they might be committed
toward an astrocytic cell fate (Figures S6E and S6F).
Interestingly, activation of stress-signaling cascades (Fig-
ure 7A) and alterations in nuclear architecture (Figures 7B and
S7A) were detected in astrocytes upon osmotic stress similarly
to neurons. We next asked whether differences in FUS import
could explain the distinction. We confirmed that TNPO is the
responsible shuttling factor in astrocytes, because its inhibition
led to increased amounts of FUS in the cytosol (Figure 7C),
whereas blocking importin a/b did not (Figure S7B). This finding,
in conjunction with our observation that nuclear TNPO overex-
pression reduced FUS mislocalization (Figure 5H), raised the
possibility that astrocytes might express higher TNPO levels,
thereby efficiently transporting FUS to the nucleus, even under
osmotic stress. However, when comparing TNPO levels of astro-
cytes with a panel of reacting cell types, we did not detect an
increase in astrocytic TNPO 1 or 2 (Figure S7C). Moreover,
Figure 6. Astrocytes Are Spared from Stress-Induced Cytoplasmic
Translocation of FUS
(A and B) In mouse brain slices FUS redistribution due to sorbitol treatment
was observed in CD68-positivemicroglial cells (A), whereas it stayed nuclear in
mouse GFAP-positive astrocytes (B).
(C) Pure human NSC-derived astrocyte cultures, labeled with the astrocyte
markers VIM and GFAP, did not show FUS cytoplasmic redistribution upon
osmotic stress.
(D) Quantification of non-nuclear FUS in human astrocytes confirmed their
non-reactivity to hyperosmolar stress (n = 8–15; data are represented as box
and whisker plot).monitoring TNPO levels during osmotic stress did not reveal an
increase of TNPO in astrocytes (Figure S7D).
Intriguingly, when monitoring the subcellular localization of
TNPO upon osmotic stress in pure astrocyte cultures, we did not
detect a cytoplasmic shift (Figures 7D, 7E, S7E), as seen in neu-
ronsandother reactingcells.ThecorrelationbetweenTNPO local-
ization and FUS redistribution was further confirmed comparing
FUS reactive and non-reactive cells with normal or altered TNPO
localization, respectively, in mixed neuronal and astrocytic cul-
tures (FigureS7F). Togetherwith theobservation that only nuclear,
and thus supposedly shuttling, TNPO rescued FUS redistribution
(Figure 5H), we postulate that cytoplasmic retention of TNPO im-
pairs its import function, and that this specifichyperosmolar stress
response is not implemented in astrocytes.
It was previously reported that astrocytes are spared from
pathological findings in ALS patients with FUSmutations (Mack-
enzie et al., 2011), so we wondered whether that might also be
true for FTLD-FUS, in which TNPO1 was found to coaggregate
in FUS-positive inclusions. TNPO1 immunostaining of FTLD-
FUS post-mortem tissue showed numerous neuronal cyto-
plasmic inclusions, intranuclear inclusions, and neuropil threads
in the frontal cortex as previously observed (Brelstaff et al.,
2011). Intriguingly, double immunostaining with GFAP showed
no colocalization between TNPO1 pathological inclusions and
reactive astrocytes in FTLD-FUS (Figures 7F and S7G).DISCUSSION
The RPB FUS marks pathological cytoplasmic inclusions in
distinct subtypes of ALS and FTD with early disease onset.
Although FUS can shuttle between the nucleus and the cyto-
plasm, its physiological steady state is predominantly nuclear.
This equilibrium is maintained by constant nuclear import
through TNPO, but can be shifted to the cytosol either by inhibi-
tion of this shuttling receptor (Dormann et al., 2010) or genetic
disruption of its NLS by ALS-causing mutations (Kwiatkowski
et al., 2009; Vance et al., 2009). Because FTD-FUS cases
show no underlying mutations, we tested the stress-induced nu-
cleocytoplasmic shuttling of endogenous FUS in an ex vivo
mouse CNS model and human neural networks. We identified
hyperosmolar stress as a robust driver of cytoplasmic transloca-
tion of wild-type FUS and other cargos of TNPO in neurons. This
diffusion-based reaction was independent of SG formation and
classical osmoregulatory pathways, and was potentiated by
transcriptional inhibition. Importantly, this specific response
was mediated by cytoplasmic accumulation and impaired shut-
tling of TNPO, but not other transporting factors, and was sur-
prisingly absent in astrocytes, which lack pathological TNPO ac-
cumulations in FTLD-FUS patient brains.Cytoplasmic Translocation and Stress Granule
Incorporation of FUS Are Uncoupled
Recruitment of FUS to SG resulting from a variety of stressors
has been widely demonstrated, albeit most studies usedMerged images always include nuclear DAPI staining. OSM, hyperosmolar
stress.
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Figure 7. Despite Their Reaction to Hyper-
osmolarity, Astrocytes Do Not Show This
TNPO-Specific Stress Response
(A) Immunoblots of TonEBP, ph-ERK, and ph-
ATF2 confirmed the activation of general stress
signaling cascades in human astrocytes compared
with GAPDH and non-phosphorylated kinases
(ERK, p38).
(B) Hyperosmolarity-induced nuclear rearrange-
ment in human astrocytes, as observed by alter-
ations in DNA (DAPI) and nuclear splicing speckles
(SC-35) pattern.
(C) In human astrocytes expressing the RFP-tag-
ged peptide inhibitor M9M (C), TNPO1 was
blocked and FUSwas shifted to the cytoplasm due
to impaired nuclear import.
(D–E) TNPO1 subcellular distribution and nuclear
FUS localization were unchanged upon osmotic
stress in human astrocytes, shown in representa-
tive images (D) (merge with nuclear DAPI staining
and astrocytic markers GFAP and VIM) and
quantification of cytoplasmic TNPO1 (E) (n = 18–20
images, data are represented as box and whisker
plot).
(F) Representative images of immunohistochem-
ical staining of FTLD-FUS post-mortem human
brain tissue. TNPO1-positive neuronal cyto-
plasmic inclusions were observed in the frontal
cortex of a FTLD-FUS case, and GFAP immuno-
histochemistry showed an extensive network of
reactive astrocytes and astrocytic processes. No
TNPO1 immunoreactivity colocalized with GFAP-
positive astrocytes.
OSM, hyperosmolar stress.overexpression of the wild-type or NLS mutant protein (Ander-
son and Kedersha, 2009; Bentmann et al., 2012; Bosco et al.,
2010; Vance et al., 2013). In our study, we focused on endoge-
nously expressed FUS within differentiated neurons in their nat-
ural microenvironment and show that nuclear FUS is unaffected
by cytoplasmic SG formation induced by arsenite.
Hyperosmolarity was recently reported to drive endogenous,
nuclear FUS to cytoplasmic SGs, which were hypothesized to
actively sequester endogenous FUS out of the nucleus to specif-
ically localize certain mRNAs and proteins into these structures
(Sama et al., 2013). In contrast, we found that FUS cytoplasmic
localization was unaffected by inhibition of SG formation (Figures
2 and S2). This surprising finding indicates that SGs are not the
driving factor pulling nuclear FUS into the cytoplasm. Supporting
this, prolongation of cytoplasmic SGs could not retain endoge-
nous FUS, which escapes these stabilized SGs to return to the
nucleus in its own timeline of stress reaction (Figure 2F). Our
data demonstrate that cytoplasmic translocation and SG parti-
tioning of FUS are two independent processes, and that the996 Cell Reports 24, 987–1000, July 24, 2018former precedes the latter. Importantly, hyperosmolar stress in-
cites both cytoplasmic FUS relocation and formation of TIAR/
G3BP-positive granules, into which redistributed FUS is
incorporated.
TNPO as a Stress Response Sensor or a Cytoplasmic
Chaperone?
When dealing with sudden stress, cells utilize a wide range of
mechanisms to temporarily block metabolic processes,
including DNA replication, transcription, mRNA export, and
translation. At the same time, they initiate stress-defense mech-
anisms via transcriptional activation, alternative splicing, and
translational surge of stress response proteins. This binary
response requires ways to selectively shut down or activate sin-
gle factors or groups of functionally related proteins. On a trans-
lational level this task is performed by SGs, which selectively re-
cruit cytoplasmic mRNAs and RBPs. Regulation of nuclear
processes is achieved by changes in subcellular distribution
and altered association with multiprotein complexes of many
splicing and transcription factors. The observed stress-induced
shift of FUS to the cytoplasm and the concomitant decrease in its
nuclear abundance are accompanied by loss of nuclear function
(Figures 1F, S1M, and S1N), comparable with FUS knockdown
(Reber et al., 2016). Moreover, the dynamic redistribution upon
osmotic stress is shared by many, if not all, PY-NLS-containing
proteins and correlates with the cytoplasmic shift of TNPO.
Intriguingly, most experimentally validated PY-NLS-containing
cargos are RBPs, whereas about 60% of proteins with predicted
PY-NLS are involved in RNA transcription or processing (Lee
et al., 2006). We thus propose that the subcellular redistribution
of nuclear RBPs could act as a specific response to hypertonic
pressure, caused by the cytoplasmic retention of TNPO.
Moreover, the increased cytoplasmic localization of TNPO
might be a protective mechanism to counteract aberrant phase
transitions of FUS and other aggregation-prone TNPO1 cargoes
during stress. Indeed, several recent studies showed that nu-
clear import receptors, including TNPO1, function as cyto-
plasmic chaperones to prevent aberrant phase transitions of ag-
gregation-prone RBPs with prion-like domains (Guo et al., 2018;
Hofweber et al., 2018; Qamar et al., 2018; Yoshizawa et al.,
2018). Aberrant phase transitions of such proteins may be
favored because of macromolecular crowding during osmotic
stress (Bounedjah et al., 2012), necessitating elevated levels of
TNPO1 in the cytoplasm under these conditions.
Astrocytic Resistance to TNPO-Specific Stress
Response
Here, we report the unique and surprising unresponsiveness of
mouse and human astrocytes to osmotic stress, despite the
comparable activation of stress cascades and no differences
in their osmotolerance toward nuclear rearrangement. In
contrast, we identified a striking divergence in the reaction of as-
trocytic TNPO and FUS upon hyperosmolarity (Figures 6, 7, S6,
and S7). Astrocytes as one of the most resistant cell types in the
brain express unique water channels called aquaporins (AQP)
that allow passive water flux across their cell membrane (Risher
et al., 2009). Indeed, AQP4 and AQP9 are upregulated upon hy-
perosmolarity in astrocytes through activation of MAPK- and To-
nEBP-mediated pathways (Arima et al., 2003; Yi et al., 2013),
thereby potentially enabling their observed resistance. Such an
astrocyte-specific osmoregulation might thus explain the unal-
tered localization of TNPO and its cargo, whereas it did not pre-
vent alterations in nuclear structure, suggesting that FUS release
from nuclear complexes alone cannot explain the disparities
(Figure 7).
Intriguingly, this astrocytic resistance is also seen in disease,
where pathological inclusions are found in neurons and other
glial cells, but not astrocytes, both in ALS-FUS (Mackenzie
et al., 2011) and in FTLD-FUS (Figure 7). Many studies have
shown that astrocytes are affected in several neurodegenerative
diseases and contain insoluble protein inclusions such as tau de-
posits in FTD (Komori, 1999) or phosphorylated TDP-43 aggre-
gates, specifically in astrocytes in Alexander disease (Walker
et al., 2014). Thus, the coinciding fact that astrocytes are spared
from FUS/TNPO pathology and from hyperosmolarity-induced
mislocalization leads to the attractive hypothesis that osmotic
imbalances could play a critical role in disease initiation.Cytoplasmic Redistribution of FUS as an Initial Step in
the Development of FUS Pathology
A ‘‘multiple-hit model’’ has been proposed for the initiation of
FUS pathology, postulating that any event resulting in
abnormal cytosolic FUS localization, combined with cellular
stress or genetic risk factors favoring aggregation, may trigger
formation of insoluble FUS inclusions (Dormann et al., 2010).
In this context, recruitment of cytosolic FUS to SGs has
been widely hypothesized to act as a ‘‘second hit,’’ implying
that any insult triggering SG formation in the CNS might initiate
inclusion formation (Dormann and Haass, 2011). ALS-causing
mutations that disrupt the NLS are likely the ‘‘first hit,’’ result-
ing in diffuse cytoplasmic FUS (Scekic-Zahirovic et al., 2016;
Vance et al., 2013).
In sporadic FTD-FUS cases, however, the signal that initially
renders FUS cytosolic is unclear. Our findings suggest that hy-
perosmolar pressure might present a specific insult leading to
cytoplasmic mislocalization of FUS, a notion strongly sup-
ported by the coaggregation of TNPO and FET proteins in
FTD-FUS, but not ALS-FUS. Intriguingly, mislocalization of
FET proteins upon hypertonic stress mimics the pattern of pa-
thology seen in FTD patients. TAF15 co-localized completely
with FUS in our stress regimen, as well as in patient inclusions,
whereas smaller amounts of EWS were detected in the cyto-
plasm upon stress, consistent with the observation that only a
portion of FUS inclusions are EWS-positive (Mackenzie and
Neumann, 2012). The fact that other TNPO cargo proteins
have not been found in pathological inclusions (Neumann
et al., 2011), while these also mislocalize upon sorbitol stress,
indicates that additional factors may determine final aggregate
formation and specificity. One such factor may be their differen-
tial response to the ‘‘second hit,’’ i.e., incorporation into SGs,
despite their cytoplasmic localization. In line with this, two
recent studies showed the critical role of RNA-binding specific-
ities in the incorporation of RBPs within phase-separated gran-
ules (Langdon et al., 2018; Maharana et al., 2018). Therefore, it
is plausible that the distinct RNA-binding specificities of these
proteins may lead to their differential incorporation into SGs
and eventually into pathological inclusions. Moreover, the
strong aggregation propensity (Sun et al., 2011), as well as
the potential prion-like properties (Hock and Polymenidou,
2016) of the highly homologous FET proteins, may render
them particularly vulnerable to such a ‘‘second hit.’’
What are the conditions that may lead to osmotic imbalance in
the human brain? Multiple studies report an increased risk of
developing FTD after severe head trauma (Kalkonde et al.,
2012; Rosso et al., 2003; Wang et al., 2015). A serious and com-
mon complication of traumatic brain injury (TBI) is cerebral
edema, defined as increase in brain water content. The treat-
ment of choice for releasing intracranial pressure is hyperosmo-
lar therapy (Ropper, 2012). Infusion of either mannitol or hyper-
tonic saline solutions rapidly raises plasma osmolarity, thereby
reducing brain volume. Because both hypertonic saline and
mannitol trigger macromolecular crowding and elicit FUS mis-
localization, it is tempting to speculate that the reported associ-
ation of FTD to TBI might be due to the effect of hyperosmolar
therapy rather than the head impact itself. This idea is under-
scored by the fact that FTD-FUS is a sporadic, early-onsetCell Reports 24, 987–1000, July 24, 2018 997
disease (Lee et al., 2013) characterized by cytoplasmic aggre-
gates containing all FET proteins and TNPO (Neumann et al.,
2011). Because the implications for public health are significant,
further investigation is urgently needed to clarify the conse-
quences of hyperosmolar therapy in the brain.
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Rotorgene6000 Corbett N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Magdalini
Polymenidou (magdalini.polymenidou@imls.uzh.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cortico-hippocampal brain slice culture
Cortico-hippocampal brain slice preparation was adapted from previously published protocols (Falsig and Aguzzi, 2008; Falsig et al.,
2008). Slices were prepared from 5-8 day old C57BL/6J pups. After decapitation the brain was removed quickly under sterile con-
ditions and placed in a drop of ice cold GBSSK (137 mM NaCl, 5 mM KCl, 0.845 mM Na2HPO4, 1.5 mM CaCl2 x 2H2O, 0.66 mM
KH2PO4, 0.28 mM MgSO4 x 7H2O, 1 mM MgCl2 x 6H2O, 2.7 mM NaHCO3, 33.33 mM Glucose, 1 mM kynurenic acid, pH to
7.2–7.4). The hippocampus plus the surrounding cortical regions were dissected under a binocular and placed on a tissue chopper
in an orientation that the hippocampus lies stretched out in a 90 degree angle to the cutting blade with the cortical parts on top.
350 nm slices were cut and separated under the binocular in GBSSK. Two slices each were placed in Millicell-CM inserts in 6
well plates, residual GBSSK was removed, cold forebrain culture medium was added to the bottom of the well and the plate was
moved to the incubator. Mediumwas changed the following day to remove residual buffer. Slice cultures weremaintained in forebrain
culture medium (50% BME with Earles salt sol., w/o L-Glutamine, 25% Earle’s salt solution, 25% heat inactivated horse serum, sup-
plemented with 1% glucose, 1% penicillin/streptomycin and GlutaMAX C in a humidified incubator at 37C with 5% CO2 for at least
3 weeks before the start of the experiment to stabilize after preparation.
Mice housing and breeding were in accordance with the Swiss Animal Welfare Law and in compliance with the regulations of the
Cantonal Veterinary Office, Zurich.
NSC derivation and neural differentiation
iPSC and NSC derivation and their differentiation into neurons and astrocytes will be described in detail in Hruska-Plochan et al.
(manuscript under review). Briefly, iPSCswere generated from control human early post natal dermal fibroblasts via episomal reprog-
ramming using plasmids coding for Oct3/4, Sox2, Klf4 and p53-shRNA. Resulting iPSC colonies were manually picked and cultured
in non-adhesive conditions to generate embryoid bodies which upon plating onto poly-L-ornithine/laminin coated plastic in NSCme-
dium containing bFGF induced the formation of neuronal rosettes. These were manually dissected and enriched via three consec-
utive passaging steps. Patches of cells with a distinct morphology migrating out of the neuronal rosettes were then manually picked
and considered neuronal stem cell clones, which were expanded for future differentiation. For experiments, NSCswere differentiated
into neuronal cultures for 25 days using Forskolin, Ec23 and SAG with the addition of BDNF, GDNF and CNTF from day 11 on. After
25 days cells were subcultured and recovered in D3medium. At this point the neural culture already contains neurons, astrocytes and
oligodendrocytes. To obtain pure astrocytic cultures cells from the differentiated neural cultures were replated in astrocytemedium at
day 25 and remaining neurons were killed off via 2-3 passages. For experiments, astrocytes were plated sparsely which promotes
their maturation.
Post-differentiation astrocytes and neural cultures were cultured on Matrigel (230mg/ml) in astrocyte medium (DMEM-F12, 1%N2,
0.2% penicillin/streptomycin, 1%GlutaMAX, 20ng/ml CNTF) or ‘D3 medium‘ (DMEM-F12, 1%B27+, 1%GlutaMAX, 20ng/ml BDNF,
20ng/ml GDNF, 20ng/ml CNTF, 1% N2, 1% penicillin/streptomycin) respectively in a humidified incubator at 37C with 5% CO2.e4 Cell Reports 24, 987–1000.e1–e7, July 24, 2018
Cell Lines
Cells weremaintained in a humidified incubator at 37Cwith 5%CO2. HEK293, NSC-34 and SHSY5Y cells were grown in DMEM-F12
with 10% FBS and 1% penicillin/streptomycin. 2-5 days prior to experiments, NSC-34 were switched to differentiation medium
(DMEM-F12, 1%B27+, 1%GlutaMAX, 10ng/ml BDNF, 10ng/ml GDNF, 1%N2, 0.2% penicillin/streptomycin) and grown onMatrigel
(90mg/ml) coated culture dishes.
METHOD DETAILS
Stress and inhibitor experiments
For stress experiments, sorbitol, urea, and sucrose were directly dissolved in the medium to add an additional osmolarity of 0.4M. To
reach hypoosmolar conditions medium without Earls salts was used. To induce oxidative stress, 0.25-0.5mM sodium arsenite was
added to themedium. Different compounds were used at indicated concentrations in the culture medium: cycloheximide (100mg/ml),
emetine (100mM), GSK-626616 (50mM), actinomycin (5mg/ml), DRB (5,6-Dichlorobenzimidazole 1-b-D-ribofuranoside, 10mM), Adox
(20mM), SB202119 (20mM), SB203580 (20mM), SKI (20mM), wortmannin (5mM), SP600125 (20mM), Go¨ 6983 (5mM), leptomycin B (10n),
staurosporine (1mM), Nu 7441 (1mM). In case of inhibitor treatment parallel with stress experiments, all inhibitor compounds were
added 15min prior to the start of the stress insult except otherwise indicated. To induce nuclear import of GR2-GFP2-fusion proteins,
cells were incubated for 20 min with dexamethasone (5mM).
Transient transfection and siRNA-mediated knock down
Transient plasmid transfections were achieved using Lipofectamine2000 Transfection Reagent according to manufacturer’s pro-
tocol with 1ng/ml DNA. siRNA transfections were performed with Lipofectamine2000 at a final concentration of 25nM siRNA or
40nM (TonEBP). Culture medium was exchanged 24h after transfection and the knock down was analyzed 48h post-transfection
by immunoblotting and immunostaining.
Immunofluorescence staining
For immunostaining cultures were first fixed in 4% Formaldehyde in PBS for 10 min (cells) and overnight (ON) (slices). After
washing, permeabilization and blocking buffer (10% donkey serum and 0.3% Triton X-100 in PBS) was added for 1h (cells) or
4h (slices). Primary antibodies were added in blocking buffer and incubated for approximately 2h at room temperature (RT) or
ON at 4C for cells or 2-3 days for slices (see antibody list). Cultures were washed three times in PBS before incubating them
with 488-, 594 or 647-Alexa-conjugated secondary antibodies raised in donkey (1:1000) for 1h at RT (cells) or ON at 4C (slices)
and subsequently washed with PBS. For slice cultures, additional DAPI (1mg/ml) was added for 30 min in PBS. After washing, cells
and slices were mounted with mounting medium anti-fade with DAPI and left to harden at RT for at least 24h in the dark before
imaging.
PolyA RNA in situ hybridization
Cells were fixed for 10 min at RT in 4% formaldehyde in PBS, washed in FISH buffer (2X saline sodium citrate (SSC) with 10%
Formamide, then permeabilized for 30 min in 0.1% Triton X-100 and 0.1% BSA in FISH buffer. After washing in FISH buffer,
hybridization with 0.5mM oligo(dT)30-Cy3 probe was carried out for 4 h at 37
C, followed by a washing step at 37C in FISH
buffer. Subsequently, immunostaining with primary antibodies was carried as mentioned above, with PBS exchanged to SSC
buffer at all steps.
SDS-PAGE and Immunoblotting
Cells were scraped in ice cold lysis buffer with Benzonase and 2mM MgCl2 and homogenates were cleared 5 min at 17 000 g. To
collect slice tissue, several brain slices were scraped into lysis buffer with Benzonase and 2mM MgCl2 and subjected to 2 times
30 s of homogenization at full speed with a Minilys device in tubes containing ceramic beads. Protein concentration was adjusted
based on BCA assay and lysates were boiled in loading buffer with reducing agent before loading the samples on Bolt 12% Bis-
Tris gels. For immunoblots, gels were transferred onto nitrocellulose membranes using iBlot 2, which were blocked with 5% non-
fat skimmed powder milk in PBS-Tween and probed with primary antibodies ON (see list) followed by secondary HRP-conjugated
goat anti mouse or rabbit IgG antibodies (1:5000, 1:10000, respectively). Immunoreactivity was visualized by chemiluminescence.
Sequential Insolubility Assay
Slice tissue was subjected to increasing detergent stringency (1. salt buffer, 2. RIPA, 3. 1% Triton-X, 4. 2% Sarkosyl) separating
soluble and insoluble material after each step via centrifugation. Initially, slices were scraped in salt buffer (10mM Tris, 250mM
NaCl, 1mM EDTA, 1mM DTT, complete protease inhibitor cocktail, PhosStop) containing Benzonase and 2mM MgCl2 and homog-
enized using Minilys for twice 30 s at full speed followed by a 30 min centrifugation step at 4C with 17 000 g. The supernatant
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incubation, pellet and supernatant were separated again by centrifugation. This process was repeated until a sarkosyl-insoluble
pellet was obtained, which was dissolved in original volume of loading buffer and subjected to immunoblotting with all other sam-
ples as described above.
Splicing reporter assay
Cells were co-transfected with 400 ng of the SCN4A reporter plasmid and 600 ng empty filler plasmid (pcDNA3.1(+)) using Lipofect-
amine 2000 according to the manufacturer’s instructions. After 48h cells were stressed for 2h with 0.4M sorbitol. Thereafter, half of
the cells were harvested using Trizol for subsequent standard RNA isolation. The purified RNA was DNase treated using the TURBO
DNA-free according to themanufacturer’s manual. Reverse transcription of total RNAwas performed using the AffinityScript Multiple
Temperature cDNA Synthesis Kit according to the manufacturer’s manual. RT-qPCR was performed using 3 ml cDNA, 1 x MESA
GREEN qPCR Mastermix Plus for SYBRR Assay No ROX and each 8 ml forward and reverse primer in a total volume of 15 ml per re-
action. qPCR primers for SCN4A were used as published in Reber et al., 2016 and primers for control genes are listed in Table S1 in
Supplemental Information. Samples were measured in duplicates in a Rotorgene6000. The following cycling conditions were used:
95C, 5min; 95C, 15 s; 60C 1min; 40 cycles. A melting curve was recorded from a temperature gradient from 65C to 95C, 5 s/C.
Analysis was performed using the Rotor-Gene 6000 Series Software V1.7. The other half of the cells were lysed using RIPA buffer. The
lysate was centrifuged 15min at 16’000 g at 4C to remove insoluble components and the supernatant was re-suspended in 4X LDS-
loading buffer for subsequent SDS-PAGE western blot analysis with the primary antibodies (rabbit anti-actin (Sigma Aldrich, A 5060)
or rabbit anti-FUS (homemade, (Raczynska et al., 2015)), respectively) and with fluorescence-labeled secondary antibody (IRDye
800CW Goat anti-Rabbit IgG (H + L)). Membranes were analyzed with the Odyssey Infrared Imaging System.
Labeling of newly synthesized proteins
Newly synthesized proteins were labeled using a combination of the Click-IT AHA and the Click-IT TAMRAProtein Analysis Detection
Kit according to the manufacturer‘s protocol. Briefly, cells were washed in PBS and methionine-free DMEMmedium was added for
45 min after which translation inhibitors were added to the medium for 15 min prior to addition of AHA (50mM, L-Azidohomoalanine)
for 1h. Cells were then fixed for 10 min, washed in PBS and permeabilized in 0.25% Triton-X, 1% BSA in PBS. After washing in 3%
BSA in PBS the TAMRA reaction mix was added for 30 min protected from light. Samples were then subjected to additional antibody
staining as described.
Image acquisition
All confocal microscopy except for patient tissue section analysis was performed at the ZMB core facility of the University of Zuerich
with an inverted Leica SP5 microscope, equipped with lasers for 405, 488, 561 and 633 nm excitation. Images were acquired using
48-fold line averaging with a 40x1.25 or 63x1.4 oil objective at different zooms. Settings were kept identical between groups of sam-
ples within an experiment. For quantification neuron andNSC-34 imageswere takenwith 63x1.4 objective at 1.7x zoom, slice images
with 63x1.4 objective at 4x zoom and astrocyte images with 40x1.25 objective at 1.7x zoom; exception: For quantification of FUS and
polyA mRNA in the Aly/REF knock down experiment single cells with successful KD (nuclear retained mRNA and reduced Aly/REF
levels) were imaged with 63x1.4 objective at 8x zoom.
Patient tissue sections and analysis
Patient material has been collected from donors for or from whom a written informed consent for a brain autopsy and the use of the
material and clinical information for research purposes has been obtained by the Queen Square Brain Bank for Neurological dis-
eases. In total, hippocampus, frontal and temporal cortices of four FTLD-FUS cases (2 NIFID and 2 aFTLD-FUS) were analyzed.
8 mm thick tissue sections were cut from paraffin embedded tissue. Endogenous peroxidase activity was blocked with 0.3% H202
in methanol followed by pressure cooker pre-treatment in citrate buffer pH 6.0. Sections were treated with 10% dried milk solution
to block non-specific binding. Tissue sections were incubated with the primary anti-TNPO1 (Abcam, 1:200) antibody for 1 hr at room
temperature, followed by biotinylated anti-mouse (Dako; 1:200), ABC complex (Dako) and visualized using TSA fluorescein kit. Sec-
tions were then incubated with anti-GFAP (Dako, 1:1000) for 1 hr at room temperature followed by the secondary anti-rabbit Alexa
Fluor 568 (1:500). Sections were counterstained with 4’-6-diamidino-2-phenylindol (DAPI) and viewed under a Leica DM5500B fluo-
rescence microscope using 3D deconvolution post-processing.
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
To measure FUS (or other proteins/mRNA) amounts outside of the nucleus a threshold was applied to DAPI and FUS frames. The
thresholded DAPI mask was subtracted from the FUS image. Positive pixels of the resulting image containing only non-nuclear
FUS pixels were measured and given as a percentage of the overall FUS pixels in the original image. For slice image quantification,
only pixels overlaying with the neuronal marker NEUN were taken into calculation. For TNPO quantification in neurons this percent-
age was additionally normalized to TNPO positive area. Images for quantification were thresholded independently for each experi-
ment to achieve similar values for the non-treated control condition. Achieved percentages represent arbitrary values for comparisone6 Cell Reports 24, 987–1000.e1–e7, July 24, 2018
and not absolute numbers. Figures are displayed as box and whisker graphs except otherwise indicated together with the number of
images (n) in the respective figure legends.
Statistics
The statistical significance of two groups of results was determined by a two-tailed, unpaired t test (except paired t test for densito-
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